Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Sun Dec 18 09:21:32 UTC 2022
by
admin
on
Sun Dec 18 09:21:32 UTC 2022
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
JQ83GG8LT2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB14954
Created by
admin on Sun Dec 18 09:21:36 UTC 2022 , Edited by admin on Sun Dec 18 09:21:36 UTC 2022
|
PRIMARY | |||
|
JQ83GG8LT2
Created by
admin on Sun Dec 18 09:21:36 UTC 2022 , Edited by admin on Sun Dec 18 09:21:36 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
NON-INHIBITOR->OFF TARGET |
IC50
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
selective for alpha isoform, and leads to degradation of mutant p110 alpha PI3K subunit.
Ki
|
||
|
INHIBITOR -> TARGET |
|
||
|
WEAK INHIBITOR->TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
INHIBITOR
IC50
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
PARENT->INNOVATOR | |||
|
INHIBITOR -> TARGET |
IC50
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
IC50
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
Ki
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
IC50
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
IC50
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
COMPETITIVE INHIBITOR
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
INHIBITOR
IC50
|
||
|
INHIBITOR -> TARGET |
Ki
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
Highly selective PI3K? inhibitor when tested at 1 ?M in a broad kinase panel (344 assays). >1000-fold selective over the members of
class 2 (PI3K-C2?, PI3K-C2?), class 3 (hVPS34), and class 4 (PI3K?, PI4K?) groups of the PI3K family, PI3K-related (DNA-PK, mTOR) kinase family.
Ki
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
Selective, oral bioavailable PI3K? isoform inhibitor s more than 100-fold selective than other class I
PI3K isoforms and mTOR as well as a high degree of selectivity against a large panel of protein kinases with potential antitumor activity.
IC50
|
||
|
INHIBITOR -> TARGET |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT | CHEMICAL |
|